Ado-trastuzumab emtansine, a HER2-targeted antibody-drug conjugate was found to be associated with an ORR of 44% in NSCLC with HER2 exon 20 insertions and point mutations (89), and another HER2-targeted antibody-drug conjugate, trastuzumab deruxtecan, also showed an encouraging ORR of 55% in patients with metastatic HER2-overexpressing or HER2-mutant NSCLC whose disease had relapsed during standard treatment or was refractory to standard treatment (90). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.